Ross Feller Casey’s Brian J. McCormick, Jr., was interviewed for The American Law Journal’s latest episode —White Collared: Is the Department of Justice Targeting Corporate Executives?—that aired this week on regional cable stations.
The program focused on the fact that despite a series of billion-dollar-plus fines levied by the federal government on drug companies in recent years, no executives have faced criminal prosecution themselves.
McCormick, one of the nation’s leading mass tort and whistleblower attorneys, told the program that executives of pharmaceutical giants involved in recent major qui tam cases had to have known about questionable drug practices.
“There is no way these individuals should have escaped without any kind of individual liability,” he said.
That could be about to change, however, as government prosecutors appear poised to take a tougher stance on individual corporate leaders given the spotlight placed on the recent Volkswagen emission-rigging scandal.
“This concentration on individuals now has to have companies and their outside counsel worried. They know something has changed,” McCormick said.